Brian Abrahams
Stock Analyst
(n/a)
# 4,648
Out of 4,655 analysts
416
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Brian Abrahams
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,260 → $1,215 | $843.60 | +44.03% | 30 | Nov 1, 2024 | |
GLPG Galapagos NV | Maintains: Sector Perform | $32 → $30 | $26.89 | +11.57% | 11 | Nov 1, 2024 | |
INCY Incyte | Maintains: Sector Perform | $67 → $72 | $76.13 | -5.42% | 17 | Oct 30, 2024 | |
GILD Gilead Sciences | Reiterates: Sector Perform | $75 | $89.51 | -16.21% | 26 | Oct 29, 2024 | |
MRNS Marinus Pharmaceuticals | Maintains: Sector Perform | $3 → $1 | $0.33 | +204.97% | 8 | Oct 25, 2024 | |
SRPT Sarepta Therapeutics | Reiterates: Outperform | $182 | $123.29 | +47.62% | 31 | Oct 21, 2024 | |
IGMS IGM Biosciences | Maintains: Outperform | $17 → $20 | $16.22 | +23.30% | 14 | Oct 18, 2024 | |
VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $425 → $437 | $471.12 | -7.24% | 47 | Oct 9, 2024 | |
NBIX Neurocrine Biosciences | Reiterates: Sector Perform | $133 | $122.21 | +8.83% | 16 | Oct 8, 2024 | |
SAGE Sage Therapeutics | Downgrades: Underperform | $10 → $4 | $6.05 | -33.88% | 20 | Oct 4, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $32 → $34 | $40.47 | -15.99% | 17 | Oct 4, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $106 → $108 | $86.54 | +24.80% | 18 | Oct 4, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $292 → $269 | $173.79 | +54.78% | 33 | Oct 4, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $82 | $16.92 | +384.63% | 7 | Sep 20, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $11.17 | +159.62% | 4 | Sep 4, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $41.69 | +31.93% | 13 | Sep 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $32 | $16.65 | +92.19% | 2 | Aug 14, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $24 | $16.65 | +44.14% | 9 | Aug 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3 | $0.90 | +232.15% | 9 | Aug 7, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $13 → $12 | $9.14 | +31.29% | 14 | Aug 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $8.43 | +18.62% | 14 | Aug 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $9.09 | +32.01% | 3 | Jul 17, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $6.14 | +258.31% | 9 | Jun 5, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $50 | $3.84 | +1,202.08% | 9 | May 21, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $45 | $14.52 | +209.92% | 11 | May 7, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $15 | $10.95 | +36.99% | 14 | Oct 2, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $9 | $1.08 | +733.33% | 3 | Mar 31, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $33 | $50.30 | -34.39% | 3 | Nov 3, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $50.99 | - | 4 | Dec 4, 2017 |
Regeneron Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $1,260 → $1,215
Current: $843.60
Upside: +44.03%
Galapagos NV
Nov 1, 2024
Maintains: Sector Perform
Price Target: $32 → $30
Current: $26.89
Upside: +11.57%
Incyte
Oct 30, 2024
Maintains: Sector Perform
Price Target: $67 → $72
Current: $76.13
Upside: -5.42%
Gilead Sciences
Oct 29, 2024
Reiterates: Sector Perform
Price Target: $75
Current: $89.51
Upside: -16.21%
Marinus Pharmaceuticals
Oct 25, 2024
Maintains: Sector Perform
Price Target: $3 → $1
Current: $0.33
Upside: +204.97%
Sarepta Therapeutics
Oct 21, 2024
Reiterates: Outperform
Price Target: $182
Current: $123.29
Upside: +47.62%
IGM Biosciences
Oct 18, 2024
Maintains: Outperform
Price Target: $17 → $20
Current: $16.22
Upside: +23.30%
Vertex Pharmaceuticals
Oct 9, 2024
Maintains: Sector Perform
Price Target: $425 → $437
Current: $471.12
Upside: -7.24%
Neurocrine Biosciences
Oct 8, 2024
Reiterates: Sector Perform
Price Target: $133
Current: $122.21
Upside: +8.83%
Sage Therapeutics
Oct 4, 2024
Downgrades: Underperform
Price Target: $10 → $4
Current: $6.05
Upside: -33.88%
Oct 4, 2024
Maintains: Sector Perform
Price Target: $32 → $34
Current: $40.47
Upside: -15.99%
Oct 4, 2024
Maintains: Outperform
Price Target: $106 → $108
Current: $86.54
Upside: +24.80%
Oct 4, 2024
Maintains: Outperform
Price Target: $292 → $269
Current: $173.79
Upside: +54.78%
Sep 20, 2024
Reiterates: Outperform
Price Target: $82
Current: $16.92
Upside: +384.63%
Sep 4, 2024
Reiterates: Outperform
Price Target: $29
Current: $11.17
Upside: +159.62%
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $41.69
Upside: +31.93%
Aug 14, 2024
Maintains: Outperform
Price Target: $30 → $32
Current: $16.65
Upside: +92.19%
Aug 9, 2024
Maintains: Sector Perform
Price Target: $28 → $24
Current: $16.65
Upside: +44.14%
Aug 7, 2024
Reiterates: Outperform
Price Target: $3
Current: $0.90
Upside: +232.15%
Aug 6, 2024
Maintains: Sector Perform
Price Target: $13 → $12
Current: $9.14
Upside: +31.29%
Aug 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $8.43
Upside: +18.62%
Jul 17, 2024
Reiterates: Outperform
Price Target: $12
Current: $9.09
Upside: +32.01%
Jun 5, 2024
Reiterates: Outperform
Price Target: $22
Current: $6.14
Upside: +258.31%
May 21, 2024
Reiterates: Outperform
Price Target: $50
Current: $3.84
Upside: +1,202.08%
May 7, 2024
Maintains: Outperform
Price Target: $54 → $45
Current: $14.52
Upside: +209.92%
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $10.95
Upside: +36.99%
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $1.08
Upside: +733.33%
Nov 3, 2021
Maintains: Sector Perform
Price Target: $21 → $33
Current: $50.30
Upside: -34.39%
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $50.99
Upside: -